# Are macrolide antibiotics effective in chronic idiopathic cough?

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
23/06/2009		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
23/09/2009	Completed	[X] Results		
<b>Last Edited</b> 24/08/2016	Condition category Signs and Symptoms	[] Individual participant data		

## Plain English summary of protocol

Background and study aims

Cough is an extremely common symptom, and usually settles by itself without any treatment. A small number of people experience a more persistent cough which lasts for more than 8 weeks. In most cases there is an underlying cause for which we currently have established treatments. For cases where there is no underlying cause, or where current treatment does not improve symptoms, there is no treatment at the moment. Several patients seen in our clinic have seen an improvement in their cough with the antibiotic azithromycin. We designed this study to test the effect of this treatment in a group of patients with persistent cough, and to see if we can identify which patients may benefit from this antibiotic.

#### Who can participate?

Non-smoking subjects aged 18 to 80 (either sex) with idiopathic cough for at least 2 months.

#### What does the study involve?

Before taking part, you will be screened to make sure there is no underlying cause for your cough, and that you have had a proper trial of appropriate treatments before taking a trial drug. If you take part in this study, you will be asked to take one tablet three times a week for 8 weeks in addition to your usual medication. At each study visit we will ask you to rate the severity of your cough, and complete a questionnaire measuring different aspects of your cough. You will also provide a breath sample to measure inflammation in the lungs, and a blood sample at each visit. The study is a placebo-controlled trial, so half of the participants will be randomly allocated to take a dummy pill which resembles the active tablet but has no active effects. Neither you nor the trial staff will be aware which treatment you are receiving for the duration of the trial, but you will be informed of your treatment allocation at the end of the trial.

## What are the possible benefits and risks of participating?

The main benefits are that your cough may improve, or that you help to develop an additional treatment for patients with cough. Azithromycin is a commonly prescribed antibiotic that has been in use for many years. The main side effects that some people experience are nausea, vomiting, smell and taste disturbances, abdominal discomfort, diarrhoea and headache. Less common side effects are effects on liver blood tests, joint and muscle aches. Other side effects are rare.

Where is the study run from? Nottingham Respiratory Biomedical Research Unit (UK)

When is the study starting and how long is it expected to run for? July 2009 to July 2011

Who is funding the study? Nottingham Respiratory Biomedical Research Unit (UK)

Who is the main contact?
Dr Tim Harrison
tim.harrison@nottingham.ac.uk

## Contact information

## Type(s)

Scientific

#### Contact name

Dr Tim Harrison

#### Contact details

Nottingham Respiratory Biomedical Research Unit Clinical Sciences Building City Hospital Site Nottingham United Kingdom NG5 1PB

. .

tim.harrison@nottingham.ac.uk

## Additional identifiers

Protocol serial number

2

# Study information

#### Scientific Title

Macrolide antibiotics in the treatment of chronic idiopathic cough: a randomised double-blind, placebo-controlled, parallel-group trial

## **Acronym**

MAC

## **Study objectives**

Macrolide antibiotics are an effective treatment in chronic idiopathic cough.

#### Ethics approval required

## Old ethics approval format

## Ethics approval(s)

Nottingham Research Ethics Committee 2, 11/12/2008, ref: 08/H0408/121

## Study design

Randomised double-blind placebo-controlled parallel-group trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Chronic idiopathic cough

#### **Interventions**

Azithromycin 500 mg for 3 days followed by 250 mg three times weekly for 7 weeks or matching placebo treatment regimen.

#### Intervention Type

Drug

#### **Phase**

Phase III

## Drug/device/biological/vaccine name(s)

Azithromycin

## Primary outcome(s)

Leicester Cough Questionnaire score, measured after 8 weeks' treatment with azithromycin or placebo

## Key secondary outcome(s))

- 1. Cough severity score
- 2. Adverse effects

Measured at study visits after 4 weeks, 8 weeks and 12 weeks

## Completion date

01/07/2011

## **Eligibility**

## Key inclusion criteria

Non-smoking subjects aged 18 to 80 years (either sex) with idiopathic cough for at least 2 months

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

#### Age group

Adult

## Lower age limit

18 years

## Upper age limit

80 years

#### Sex

All

## Key exclusion criteria

- 1. Active smoking or smoking history in excess of 20 pack years
- 2. Non-idiopathic cough or other major co-morbidity including abnormal liver function tests
- 3. Medication known to interact with azithromycin

#### Date of first enrolment

01/07/2009

#### Date of final enrolment

01/07/2011

## Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre Nottingham Respiratory Biomedical Research Unit

Nottingham United Kingdom NG5 1PB

# Sponsor information

## Organisation

University of Nottingham (UK)

**ROR** 

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Nottingham Respiratory Biomedical Research Unit (UK)

# **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2016		Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes